Loading…
Chinese plasma-products company that collects blood plasma and makes albumin, immunoglobulin and clotting-factor drugs.
Chinese plasma-products company that collects blood plasma and makes albumin, immunoglobulin and clotting-factor drugs.
Sells drugs made from donated plasma, so the amount it can collect at its own stations, and therefore produce, limits growth more than demand does. Albumin and immunoglobulin make up most of sales, supplied to hospitals mostly through distributors. Spain's Grifols was long a major shareholder.
In one line: A Chinese CSL Behring/Grifols.
Moat: narrow (regulatory licence, scale, installed base). Plasma-collection licenses are capped and hard to obtain, giving incumbents a scale/supply moat.
Headquarters: Shanghai, China · Employees: 4,045
Size Shanghai RAAS Blood Products (002252.SZ) is a China Health Care company (Biotechnology) with a market value of $4.89B, the 516th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.94 on 6 Nov 2026.
Performance Over six months the shares fell 11.2%, against +2.4% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 22.0% over the last twelve months (peer median +9.9%); the operating margin is 16.7% (peer median -23.4%).
Valuation It trades at 13.7× forward earnings against a peer median of 37.3× (cheapest of 7).
Capital Return on invested capital runs 2.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.20B | CN¥7.33B | CN¥8.15B | CN¥7.94B | CN¥6.55B |
| Revenue growth | — | -10% | +3% | +21% | — |
| Gross profit | CN¥2.38B | CN¥2.66B | CN¥3.24B | CN¥3.19B | CN¥2.83B |
| EBITDA | n/a | CN¥1.82B | CN¥2.31B | CN¥2.48B | CN¥2.18B |
| Net income | CN¥1.09B | CN¥1.58B | CN¥2.19B | CN¥1.78B | CN¥1.88B |
| Free cash flow | -CN¥1.08B | -CN¥484M | -CN¥591M | CN¥1.90B | CN¥1.54B |
| Capital expenditure | CN¥476M | CN¥379M | CN¥407M | CN¥451M | CN¥226M |
| Total debt | CN¥4.24B | CN¥3.95B | CN¥93.9M | CN¥115M | CN¥3.82M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai RAAS Blood Products 002252.SZ | $4.89B | -11% | -22% | 17% | 13.7× | n/a |
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 25.5× | 16.7% |
| Beijing Tiantan Biological Products 600161.SS | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002252.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.4% | +3.8% | 6th lowest of 21 |
| 6-month return | -11.2% | +2.4% | 5th lowest of 21 |
| Distance from 52-week high | -29.1% | -23.5% | 7th lowest of 21 |
| Revenue growth (TTM) | -22.0% | +9.9% | 4th lowest of 15 |
| Operating margin | 16.7% | -23.4% | 4th highest of 15 |
| Forward P/E | 13.7× | 37.3× | cheapest of 7 |
| ROIC minus cost of capital | -2.4 pp | -11.2 pp | 4th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 40.9× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 110.0× | 28.4% | +16.4% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |